Array BioPharma Inc

Array BioPharma Inc. is a biopharmaceutical company based in Boulder, Colorado. Employing 41 people, the company generates approximately $50 million in annual revenue. Focused on the development of targeted small molecule drugs, Array BioPharma is dedicated to bringing innovative cancer treatments to patients. Their efforts encompass the discovery, development, and commercialization of these drugs, with eight registration studies currently underway for seven different drug candidates. These include binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics). Array BioPharma leverages strategic partnerships to advance its research and development efforts. These collaborations allow the company to pool resources and expertise, accelerating the development of promising cancer therapies. For more information about Array BioPharma Inc., please visit their website at arraybiopharma.com.